Supplementary Table S1: Means and proportions of clinical features of all 151 patients included in this study.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Feature** | **Categories** | **REM** | **REL** | **Sig.** |
| Age at diagnosis (in years, as means with SD) |  | 63.6 ± 10.0 | 65.7 ± 8.8 | 0.17 |
| Gender | Male (as n) | 37 (52%) | 55 (69%) | *0.045* |
|  | Female (as n) | 34 (48%) | 25 (31%) |  |
| Smoking status | never smoker (as n) | 8 (11%) | 4 (5%) | 0.18 |
|  | active smoker (as n) | 26 (37%) | 24 (30%) |  |
|  | former smoker (as n) | 28 (39%) | 33 (41%) |  |
|  | unknown (as n) | 9 (13%) | 19 (24%) |  |
| Pack years (as means with SD) |  | 35.4 ± 24.0 | 52.9 ± 40.4 | *0.018* |
| Histology  | Adenocarcinoma (as n) | 49 (69%) | 42 (53%) | 0.17 |
|  | SCC (as n) | 18 (25%) | 27 (34%) |  |
|  | LCC (as n) | 3 (4%) | 8 (10%) |  |
|  | Mixed Histologies (as n) | 1 (1%) | 3 (4%) |  |
| Stage at diagnosis | I (as n) | 34 (48%) | 25 (31%) | *0.014* |
|  | II (as n) | 25 (35%) | 25 (31%) |  |
|  | III (as n) | 12 (17%) | 30 (38%) |  |
|  | IV (as n) | 0 (0%) | 0 (0%) |  |
| Type of surgery | Lobectomy (as n) | 55 (77%) | 55 (69%) | 0.64 |
|  | Bilobectomy (as n) | 4 (6%) | 8 (10%) |  |
|  | Pneumectomy (as n) | 4 (6%) | 6 (8%) |  |
|  | Other (as n) | 8 (11%) | 11 (14%) |  |
| Adjuvant therapy | None (as n) | 47 (66%) | 43 (54%) | 0.098 |
|  | Chemotherapy (as n) | 11 (15%) | 17 (21%) |  |
|  | Radiation (as n) | 3 (4%) | 7 (9%) |  |
|  | Chemotherapy and radiation (as n) | 4 (6%) | 11 (14%) |  |
|  | Unknown (as n) | 6 (8%) | 6 (8%) |  |
| Neoadjuvant therapy | None (as n) | 61 (86%) | 73 (91%) | 0.095 |
|  | Chemotherapy (as n) | 3 (4%) | 6 (8%) |  |
|  | Radiation (as n) | 0 (0%) | 0 (0%) |  |
|  | Chemotherapy and radiation (as n) | 3 (4%) | 0 (0%) |  |
|  | Unknown (as n) | 4 (6%) | 1 (1%) |  |
| Chronic lung disease | Yes (as n) | 22 (31%) | 41 (51%) | *0.014* |
|  | No (as n) | 49 (69%) | 39 (49%) |  |
| Acute infection after surgery | Yes (as n) | 24 (34%) | 23 (29%) | 0.6 |
|  | No (as n) | 47 (66%) | 57 (71%) |  |
| OS (in months, as means with SD) |  | 85.0 ± 36.1 | 33.5 ± 34.0 | *0.0001* |
| PFS (in months, as means with SD) |  | 64.5 ± 30.5 | 11.0 ± 9.0 | *0.0001* |

P-values of student t-test for numerical and Chi2-test for categorical variables.

REM= Remission group, REL= Relapse group, SCC= Squamous cell carcinoma, LCC= Large cell carcinoma, OS= Overall survival, PFS= Progression-free survival